Why the study?
Does prophylactic anticoagulation with direct factor Xa inhibitors prevent venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair compared to low molecular weight heparins or vitamin K antagonists?
Does prophylactic anticoagulation with direct factor Xa inhibitors prevent venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair compared to low molecular weight heparins or vitamin K antagonists?
This is a protocol for a Cochrane Review to evaluate direct factor Xa inhibitors versus LMWH or VKAs for VTE prevention in orthopedic surgery patients.
Answers are grounded in this paper and cite their sources.
No practice change yet; protocol leaves comparative efficacy of factor Xa inhibitors versus LMWH/VKAs open pending review completion.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus low molecular weight heparins in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair. To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus vitamin K antagonists, in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair. To evaluate the existing clinical evidence on the risks including any adverse event (serious or not) of bleeding, skin necrosis, heparin‐induced thrombocytopenia or hepatopathy associated with the analyzed therapies, in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair.
No takes yet. Share an insight, caveat, or question.
Salazar et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: